CRNX Crinetics Pharmaceuticals, Inc.
CRNX Crinetics Pharmaceuticals, Inc.
Healthcare · Biotechnology
No longer tracked since 2026-09-03 — left the market.
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Reported EPS $-1.14 versus analyst consensus of $-1.18 (+3.7%).
full note →Against street estimates
How CRNX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Result
Aug 3 -1.18-1.14+3.7%Beat
May 7 -1.20-1.23-2.9%Miss
Feb 26 -1.37-1.29+5.7%Beat
Nov 6 '25 -1.25-1.38-10.5%Miss
Aug 7 '25 -1.10-1.23-11.8%Miss
May 8 '25 -0.95-1.04-9.2%Miss
Feb 27 '25 -0.89-0.88+1.3%In line
Nov 12 '24 -0.91-0.96-5.4%Miss
CRNX research tape
35 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Types